Secondary Amyloidosis in Crohn's Disease: Treatment With Tumour Necrosis Factor Inhibitor

Gut - United Kingdom
doi 10.1136/gut.2005.082057
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Treatment With Tumour Necrosis Factor Inhibitor Oxpentifylline Does Not Improve Corticosteroid Dependent Chronic Active Crohn's Disease.

Gut
Gastroenterology
1997English

Giant Cell Myocarditis in a Patient With Crohn's Disease, Treated With Etanercept – A Tumour Necrosis Factor-Alpha Antagonist

Canadian Journal of Gastroenterology
2001English

Amyloidosis and Renal Disease in Patients With Crohn's Disease

2020English

Amyloidosis and Crohn's Disease

Revista Espanola de Enfermedades Digestivas
MedicineGastroenterology
2011English

Increased Epithelial Uptake of Protein Antigens in the Ileum of Crohn's Disease Mediated by Tumour Necrosis Factor

Gut
Gastroenterology
2004English

Increased Mucosal Tumour Necrosis Factor Alpha Production in Crohn's Disease Can Be Downregulated Ex Vivo by Probiotic Bacteria

Gut
Gastroenterology
2002English

Successful Use of Maintenance Infliximab for Nephropathy in a Patient With Secondary Amyloidosis Complicating Crohn's Disease

Internal Medicine
Internal MedicineMedicine
2013English

E0154 Expression of Tumour Necrosis Factor- Converting Enzyme and Tumour Necrosis Factor- In Rats With Alcoholic Cardiomyopathy

Heart
Cardiovascular MedicineCardiology
2010English

Successful Treatment of Refractory Behçet’s Myositis With Tumor Necrosis Factor Inhibitor

Hong Kong Bulletin on Rheumatic Diseases
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy